Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.

Gomes B, Driessens G, Bartlett D, Cai D, Cauwenberghs S, Crosignani S, Dalvie D, Denies S, Dillon CP, Fantin VR, Guo J, Letellier MC, Li W, Maegley K, Marillier R, Miller N, Pirson R, Rabolli V, Ray C, Streiner N, Torti VR, Tsaparikos K, Van den Eynde BJ, Wythes M, Yao LC, Zheng X, Tumang J, Kraus M.

Mol Cancer Ther. 2018 Dec;17(12):2530-2542. doi: 10.1158/1535-7163.MCT-17-1104. Epub 2018 Sep 19.

PMID:
30232146
2.

Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice.

Denies S, Leyman B, Huysmans H, Combes F, Mc Cafferty S, Cicchelero L, Steppe M, De Temmerman J, Sanders NN.

Cancer Immunol Immunother. 2017 Dec;66(12):1545-1555. doi: 10.1007/s00262-017-2046-3. Epub 2017 Aug 3.

PMID:
28776079
3.

In vitro exploration of a myeloid-derived suppressor cell line as vehicle for cancer gene therapy.

Denies S, Combes F, Ghekiere C, Mc Cafferty S, Cicchelero L, Sanders NN.

Cancer Gene Ther. 2017 Apr;24(4):149-155. doi: 10.1038/cgt.2016.60. Epub 2016 Nov 18.

PMID:
27857057
4.

Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12 electrogene therapy combined with metronomic cyclophosphamide in dogs with spontaneous cancer: A pilot study.

Cicchelero L, Denies S, Vanderperren K, Stock E, Van Brantegem L, de Rooster H, Sanders NN.

Cancer Lett. 2017 Aug 1;400:205-218. doi: 10.1016/j.canlet.2016.09.015. Epub 2016 Sep 28.

PMID:
27693635
5.

Comparison of the Adipose and Luminal Mammary Gland Compartment as Orthotopic Inoculation Sites in a 4T1-Based Immunocompetent Preclinical Model for Triple-Negative Breast Cancer.

Steenbrugge J, Breyne K, Denies S, Dekimpe M, Demeyere K, De Wever O, Vermeulen P, Van Laere S, Sanders NN, Meyer E.

J Mammary Gland Biol Neoplasia. 2016 Dec;21(3-4):113-122. Epub 2016 Oct 6.

PMID:
27714576
6.

Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer.

Cicchelero L, Denies S, Haers H, Vanderperren K, Stock E, Van Brantegem L, de Rooster H, Sanders NN.

Vet Comp Oncol. 2017 Dec;15(4):1187-1205. doi: 10.1111/vco.12255. Epub 2016 Aug 9.

PMID:
27506827
7.

Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.

Denies S, Cicchelero L, de Rooster H, Daminet S, Polis I, Van de Maele I, Sanders NN.

Vet Comp Oncol. 2017 Jun;15(2):594-605. doi: 10.1111/vco.12203. Epub 2016 Mar 9.

PMID:
26961119
8.

Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs.

Denies S, Cicchelero L, Polis I, Sanders NN.

Oncotarget. 2016 Mar 8;7(10):10905-16. doi: 10.18632/oncotarget.7265.

9.

Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?

Cicchelero L, Denies S, Devriendt B, de Rooster H, Sanders NN.

Oncoimmunology. 2015 Jun 1;4(12):e1048413. eCollection 2015 Dec.

10.

Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication.

Denies S, Cicchelero L, Van Audenhove I, Sanders NN.

J Control Release. 2014 Aug 10;187:175-82. doi: 10.1016/j.jconrel.2014.05.045. Epub 2014 Jun 2.

PMID:
24887014
11.

Recent progress in canine tumor vaccination: potential applications for human tumor vaccines.

Denies S, Sanders NN.

Expert Rev Vaccines. 2012 Nov;11(11):1375-86. doi: 10.1586/erv.12.104. Review.

PMID:
23249236

Supplemental Content

Loading ...
Support Center